SureTrader
Home > Boards > US OTC > Medical - Equipment >

Zenosense, Inc. (ZENO)

ZENO RSS Feed
Add ZENO Price Alert      Hide Sticky   Hide Intro
Moderator: subslover
Search This Board: 
Last Post: 1/19/2018 3:09:14 PM - Followers: 32 - Board type: Free - Posts Today: 0



NEWS JUNE17! Yahoo Finance: Zenosense, Inc. ( OTC PINK : ZENO ) has received notice of a patent issuance in the U.S.

YTD: 266%
1 Year: 141%
(04.07.2017)


 


ZenoSense (OTC:ZENO) has carved out a unique space in a revolutionary new biomedical field that is forecast to grow to $7.2 billion in the next year. ZENO is on the vanguard of this rapid growth because it’s focusing on a disease that claims the lives of 1 in 4 Americans.(1)


About Zenosense
The Revolution In Cardiac Diagnostics

Laboratory accuracy testing in the palm of your hand -
Taking diagnosis to a new, super-sensitive, nano-magnetic level

Zenosense, Inc. (OTC:ZENO) participates in the development of transformational medical diagnostic technologies: hand-held devices used at the Point of Care replacing slow and expensive laboratory testing. Our core focus through our joint venture in MIDS Medical (http://midsmed.com/) is the development and commercialisation of MIDS Cardiac™. A hand held device being developed for use at the Point of Care for the rapid testing of cardiac markers delivering results equal or superior to laboratory gold standard accuracy within minutes. A device which can revolutionize the diagnosis and management of suspected Acute Myocardial Infarction (AMI).

Our team of professionals has world class expertise and technical know-how of the application of highly specific nano magnetic particle technology to medical testing.  This knowledge, alongside their commercial experience of the Point of Care market, puts MIDS Medical in an excellent position to commercialise MIDS Cardiac™ and become the leading innovator in this field.


Laboratory
The MIDS Medical laboratory is located at the prestigious, UK Government supported Sci-Tech Daresbury campus in the UK. Sci-Tech Daresbury is internationally recognised for leading-edge scientific research and commercial development.


Good to know
Cardiovascular disease is the leading cause of death in the Western World. Accounting for more than 17 million deaths p.a. In Europe and the US alone approximately 15-20 million patients a year visit an Emergency Department (ED) reporting chest pain which must be investigated as possibly caused by a cardiac event. Every 43 seconds someone in the US has a heart attack.

Acute Myocardial Infarction (heart attack, Acute Myocardial Infraction “AMI”) affects all of us at some point in our lives, directly or indirectly, Rapid diagnosis is key; treatment in the first “Golden Hour” being crucial to survival. Equally, early “rule out” of AMI as  the cause of chest pain can save healthcare providers $billions.


Mission
Through our Joint Venture ownership in MIDS Medical we are developing MIDS Cardiac™, a cost-effective hand held Point of Care rapid cardiac diagnostic device. MIDS Medical applies patent-protected magnetic nanoparticle detection technology and world-class technical expertise.

Our development targets the delivery of a hand held device to support high sensitivity tests to identify or discount AMI (Heart Attack), with accuracy equal or better than gold standard laboratory tests, within minutes. This will significantly accelerate the triage, diagnosis, treatment and disposition of patients reporting chest pain and with suspected Acute Myocardial Infarction.

The system is designed to be used with a minimum of training; by any ER nurse or by paramedics at the scene. We believe such a device will be in universal demand; able to meet a critical medical need and rapidly penetrate a multi-billion dollar market.


MIDS Cardiac(TM)
Rapid detection of very low levels of cardiac markers with a primary focus on troponin I and T, designed to equal or exceed gold standard laboratory levels of accuracy, at the Point of Care.

>> Proof of Market (PDF) <<


Investment Highlights

  • Addressing Lethal Global Health Threat
    Co-Developing Unique Detection Device
    Strong Partnership with Sgenia Group
    Experienced, Strong Management
    Team of Highly Qualified Biologists

Key Partnership

Zenosense has an agreement with leading European sensor developer Sgenia Group, which is developing such a device exclusively for Zenosense through its subsidiary, Zenon Biosystem. The Zenosense device, utilizing established Sgenia programming and patent-pending hardware, utilizes a single sensor to perform an infinite number of scans, creating tens of thousands of "virtual sensors." The low cost and compact design of the Zenosense device, if successfully developed, would make it possible to be worn by individuals, as well as placed in numerous sensitive areas in the healthcare setting.

Sgenia Group, known for sensor development and a supplier of sensors used in the Tokamak device for a significant, international nuclear fusion research project, also produces an algal contamination detector for use in water supply applications. It rapidly and effectively scans for the volatile organic compounds (VOCs) emitted by the target algae, a unique “chemical signature” that determines the presence or absence of the algae. The Sgenia detector is effectively an electronic “nose” that can smell this signature.

Zenon is using essential elements of these technology platforms in a development program for the MRSA/SA device to be developed for Zenosense.


Leadership

Zenosense has a streamlined management team experienced in high-level marketing in the medical sector, supported by the outsourced Zenon Biosystem scientific/development team of qualified personnel with extensive knowledge and experience in the development of sensors.

Carlos Jose Gil, BSc (Engineering) - President, CEO, CFO

Carlos Jose Gil joined the company in October 2013 as a member of the board. He has experience in high-level sales management and the development of sales teams in the health care sector. From 2012 to 2013, Gil served as a managing director of Porsche Car Spain. From 2009 to 2012, Gil was sales manager at Pharmaceutic Laboratory PersanFarma. From 1994 to 2009, Gil was a medical consultant in Medical Affairs and then an account manager at Pharmaceutic Laboratory Janssen-Cilag (Johnson & Johnson). Gil holds a Bachelor of Science in Chemical Science from Valencia University, Spain.


Development Team

J. Lama, MBA, BSc

J. Lama is an engineer with a Master of Business Administration and a Bachelor of Science (Physics). His experience includes material engineering, solid state physics, electronics, renewable energy, the automotive industry and developing technological business.

M. Querol, MS

M. Querol is a mechanical engineer with a Master of Science in Telecommunications Engineering. His experience includes market development of global solutions for Aeronautical, Naval and Defense sectors, market development of internalization strategy development, and market development of industrial engineering solutions.

M. I. Gil, DEA, BSc

M. I. Gil has a Master of Advanced Studies in Fluids Mechanics from Centro Politecnico Superior of University of Zaragoza in Spain, as well as a Bachelor of Telecommunication Engineering. Gil has wide experience in sensor technologies and advanced technical and software developing.

G. Roman Perez, PhD, MAS, BSc

G. Roman Perez has a PhD in physics from the Autonomous University of Madrid (UAM), with Cum Laude distinction. He also has a Master of Advanced Studies in Condensed Matter Physics, a Master of Biophysics and a Bachelor of Physics, all issued by UAM. His work has been published in several different publications and he has spoken at conferences in France, Italy, Spain and the USA.

Additional

The company will also rely upon a team of three biologists contracted to Zenon for the development of the Sgenia Products. This team is comprised of molecular biologists and biochemists specializing in bacterial physiology and genetics, clinical microbiology and molecular biology. All hold relevant PhDs, and two hold Masters, in disciplines highly relevant to optimizing the company’s sensor for the detection of MRSA/SA. The team’s combined skillset includes deep knowledge of the clinical genetics to be addressed in order to program and refine the sensor so that it can detect SA and ideally discriminate between MRSA and SA. Variously, members of the team are business (biotechnology) management qualified, have co-authored numerous scientific publications, taught as professor, have experience of the practical clinical setting in hospital and have co-invented patents for others.


Zenosense, Inc.
Avda Cortes Valencianas 58
Planta 5 46015
Valencia, Spain
Phone: 34-96-045-4202
www.Zenosense.net
Info@Zenosense.net

 

QualityStocks designed this iBox. Please see disclaimers on the QualityStocks website: http://qualitystocks.net/disclaimer.php

SureTrader
ZENO
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ZENO News: Zenosense, Inc.: MIDS Hybrid Strip - Successful Initial Test Results 11/16/2017 07:38:27 AM
ZENO News: Quarterly Report (10-q) 11/14/2017 04:01:30 PM
ZENO News: Quarterly Report (10-q) 08/21/2017 03:27:26 PM
ZENO News: Notification That Quarterly Report Will Be Submitted Late (nt 10-q) 08/11/2017 04:42:02 PM
ZENO News: Zenosense, Inc. - MIDS Hybrid Strip Detection Testing to Commence 07/05/2017 07:54:10 AM
PostSubject
#1156   the 57k CDEL on the ask... drogocop 01/19/18 03:09:14 PM
#1155   k sharkey12 01/16/18 08:17:54 PM
#1154   I like it enough to blow out 40k subslover 01/16/18 07:10:33 PM
#1153   u still like? sharkey12 01/16/18 07:07:46 PM
#1152   You like doubled your money when you sold. subslover 01/16/18 06:49:27 PM
#1151   anything else on the radar? tx sharkey12 01/16/18 05:47:37 PM
#1150   I should not have looked at this one sharkey12 01/16/18 05:43:07 PM
#1149   ohhhh no sharkey12 01/16/18 05:32:48 PM
#1148   I see diff levels .... and want sharkey12 01/16/18 11:14:33 AM
#1147   I always use the I_HUB private reply's as subslover 01/16/18 11:11:19 AM
#1146   so wish I could give ya my e sharkey12 01/16/18 11:08:17 AM
#1145   Your dad is 100% correct! When your trading subslover 01/16/18 11:05:55 AM
#1144   Your dad is 100% correct! When your trading subslover 01/16/18 11:05:54 AM
#1143   good for u ... I wish I sharkey12 01/16/18 10:54:00 AM
#1142   Oh yea! I only sold 15k @ 62 subslover 01/16/18 10:41:08 AM
#1141   I hope u are still long here!!!! sharkey12 01/16/18 10:35:54 AM
#1140   ZENO should go bang zoom ! :) subslover 01/14/18 12:08:16 AM
#1139   NGTF... next warrants will be higher sharkey12 01/13/18 07:52:56 PM
#1138   good for u.... sharkey12 01/12/18 06:27:36 PM
#1137   Beautiful week for ZENO! subslover 01/12/18 03:25:26 PM
#1136   more than ...... but not done with sharkey12 01/12/18 04:12:22 AM
#1135   I am not in for the flip .. sharkey12 01/11/18 01:12:13 PM
#1134   Good call dude!! subslover 01/11/18 01:03:26 PM
#1133   hahahhahahah yeppppppp ... love me some smokey sharkey12 01/11/18 01:00:39 PM
#1132   Dead head munchies lol subslover 01/11/18 12:58:35 PM
#1131   too funny sharkey12 01/04/18 10:52:36 AM
#1130   MJ Munchies LMAO subslover 01/04/18 10:30:58 AM
#1129   cant believe the size bid on NGTF ... sharkey12 01/04/18 10:24:36 AM
#1128   I need this to go well over a Mbrady4 01/04/18 08:59:53 AM
#1127   I'm still in. What I should have done subslover 01/03/18 09:52:43 PM
#1126   ur still in? thought u sharkey12 01/03/18 09:09:42 PM
#1125   I own way too much of this crapola. subslover 01/03/18 08:14:10 PM
#1124   ya... I love it in sharkey12 01/03/18 07:09:12 PM
#1123   I should have let a little go in subslover 01/03/18 01:06:39 PM
#1122   Was on IWSY most of the day with subslover 01/02/18 05:07:34 PM
#1121   u been quiet today ... hope all is well sharkey12 01/02/18 04:43:01 PM
#1120   Consolidation continues and I like the daily small subslover 12/26/17 04:55:48 PM
#1119   Accumulation continues ! .51 subslover 12/22/17 10:23:33 AM
#1118   ZENO sharkey12 12/22/17 10:14:32 AM
#1117   bingo..... great run .... sharkey12 12/21/17 08:01:07 PM
#1116   Strong resistance after .51 trade and that was subslover 12/21/17 04:13:47 PM
#1115   Must be ready for NEWS. Gotta grab more subslover 12/21/17 11:08:46 AM
#1114   not much offered at 50 sharkey12 12/21/17 10:56:04 AM
#1113   FERN is all over the place .. sharkey12 12/21/17 10:51:39 AM
#1112   49 trading ZENO sharkey12 12/21/17 10:43:42 AM
#1111   yeppp .... FINALLY sharkey12 12/21/17 10:12:40 AM
#1110   $ZENO big buyer in this today! subslover 12/21/17 09:58:53 AM
#1109   $ZENO sweet like sugar close @ 44 up 18% subslover 12/20/17 04:02:31 PM
#1108   yepppp .... been on this sharkey12 12/19/17 03:51:16 PM
#1107   $ZENO trading 40 resistance. We break we FLY HIGH!!!!!!!!! subslover 12/19/17 03:49:54 PM
PostSubject